TTK Healthcare Ltd.
Snapshot View

846.20 +54.25 ▲6.9%

20 May 2022, 04:01:00 PM
Volume: 3,883

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.ttkhealthcare.com
Market Cap 1,200.94 Cr.
Enterprise Value(EV) 952.26 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) 29.24 Trailing Twelve Months Ending 2021-12
Price-Earning Ratio (PE) 29.07 Trailing Twelve Months Ending 2021-12
Industry PE 29.26 Trailing Twelve Months Ending 2021-12
Book Value / Share 223.24 Trailing Twelve Months Ending 2021-12
Price to Book Value 3.81 Calculated using Price: 849.90
Dividend Yield 0.71 Period Ending 2021-03
No. of Shares Subscribed 1.41 Cr. 14,130,333 Shares
FaceValue 10
Company Profile

T T K Healthcare Ltd was incorporated in 1958 and went public in the same year. The company's brand wagon consists of products that are sought after by a wide range of customers. The Woodward's Gripe Water brand is the market leader in the baby care category. The Eva range of personal care products (Talc, Deodorant, Skincare) bring together the gentle touch of nature, backed by TTK's extensive research.

TTK Healthcare has an All India sales and distribution network for marketing not only their own products, but also the KIWI Brand (Shoecare), Brylcreem (Haircare) and Kohinoor and Durex brands (Contraceptives). The company also specializes in sales and distribution in India as a joint venture partner. It has a successful tie up with Sara Lee Household and Bodycare Pvt. Ltd. and TTK-LIG Ltd. The company's distribution network comprises of 2800 redistribution stockists who cover both the urban and rural consumers.

TTK Healthcare has three Strategic Business Units

  • Pharamaceuticals Divison - TTK Healthcare's Pharmaceuticals Division has many breakthrough herbal and allopathic formulations, across various therapeutic segments. The range includes calcium supplements, haematinics, cervical dilators, thrombolytic agents, rejuvenators, multimineral supplements, liver correctives and pain management products.
  • Consumer Products Division - The Consumer Products Division(CPD) markets and distributes Woodward's Gripe Water - the undisputed market leader in the baby care category - and the recently introduced Woodward's Baby Soap. Besides handling the national distribution of Durex and Kohinoor condoms, the division also distributes Brylcreem Haircare and Toiletry Products and Kiwi's shoe care range.
  • Biomedical Devices Division- The TTK Heart Valve Division manufactures and distributes India's first indigenous heart valve prosthesis - the tilting-disc TTK Chitra Heart Valve. The only Indian-made heart valve, it is also the most price-friendly and so far nearly 18,000 Chitra valves have been successfully implanted in patients. Initially conceived in 1978, the heart valve being a critical implant, went through the most painstaking development for 12 years at the prestigious Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), Trivandrum, India - an autonomous institute under the Department of Science and Technology, Government of India.

TTK the three letters that stand for quality consumer products at affordable prices. A reputation built across eight decades. An organization that started out as an indenting agency and grew to what it is today with path-breaking marketing ideas. Those core values that created TTK into a force to be reckoned with continue to define the framework of the TTK Group even today.

Product range of the company includes:

Personal care- Eva range of women’s personal care products

Pharmaceuticals

  • Calcium Supplement Range
  • Delivery Care Range
  • Women's Care Range
  • Haematinic Range
  • Pain Management Range
  • Neurotrophic Range
  • Gastro Intestinal Range
  • Male Fertility Range
  • Nutritional Range
  • Cardiac Care Range

Baby Care:

  • Woodward’s Baby Bath
  • Woodward’s Gripe Water

Animal Care

  • Livestock- Wide range of medicines, tonics and productivity boosters.
  • Poultry- High quality medicines and feed supplements for good productivity
  • Medicines, tonics and supplements for Pets.

Heart Valve - India's first indigenous heart valve prosthesis - the tilting-disc TTK Chitra Heart Valve.

Food - TTK Ready-to-fry Snack Pellets are available in a variety of flavors, shapes, colours and designs

Maps- The Publications Division of TTK Healthcare is the largest producer of maps and map-based publications in the private sector.

Achievements/ recognition:

  • Besides being the first pharmaceutical company in India to be awarded the ISO certification by BIS, TTK Healthcare was also the first to launch technology-driven life-saving products like Urokinase and Dopamine.
  • The first company to launch technology driven life saving products like Urokinase and Dopamine
  • The first to develop a product based on traditional knowledge - LACTARE for Lactation

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+6.85%
1 Week
+13.02%
1 Month
+10.07%
3 Month
+18.33%
6 Month
+27.95%
1 Year
+44.30%
2 Year
+98.45%
5 Year
+9.02%
10 Year
+147.79%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 16.07 12.64 14.94 18.46 13.16 9.52 10.25 5.01 17.37
Return on Capital Employed (%) 22.23 18.12 20.71 23.85 18.63 15.42 15.46 8.28 13.53
Return on Assets (%) 7.07 5.51 6.27 7.85 6.38 5.28 5.99 2.94 10.15

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds 98 107 118 136 157 233 251 249 295 308
Non Curr. Liab. 11 27 28 16 8 2 2 7 4 7
Curr. Liab. 100 106 129 150 120 168 157 172 189 206
Minority Int.
Equity & Liab. 209 240 275 303 285 403 411 427 488 521
Non Curr. Assets 55 77 109 119 118 147 139 129 113 111
Curr. Assets 154 163 166 184 167 256 272 298 375 410
Misc. Exp. not W/O
Total Assets 209 240 275 303 285 403 411 427 488 521

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-12 Rs. Cr. TTM
Net Sales 382 416 483 519 528 578 628 646 637 771
Other Income 7 6 7 6 6 8 8 9 10 15
Total Income 389 422 489 524 534 585 636 655 647 785
Total Expenditure -362 -396 -453 -478 -489 -535 -578 -617 -602 -715
PBIDT 27 26 36 46 44 50 57 37 45 71
Interest -3 -3 -4 -3 -3 -5 -3 -3 -2 -3
Depreciation -3 -3 -6 -7 -12 -15 -15 -14 -14 -13
Taxation -7 -7 -10 -13 -10 -12 -15 -7 9 -16
Exceptional Items 8 2
PAT 14 12 16 23 19 18 24 12 46 41
Adjusted EPS 18 16 21 29 24 13 17 9 33 29

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 6 24 13 39 37 18 25 17 20 96
Cash Fr. Inv. -4 -1 -15 -49 -27 5 -23 10 -13 -77
Cash Fr. Finan. -1 -2 2 3 -11 -23 -7 -31 -10 -17
Net Change 1 22 0 -7 0 0 -4 -4 -4 2
Cash & Cash Eqvt 62 83 84 77 77 19 15 11 8 10

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 74.56 74.56 74.56 74.56 74.56 74.56 74.56 74.56 74.56
Public 25.44 25.44 25.44 25.44 25.44 25.44 25.44 25.44 25.44
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Mon, 16 May 2022
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 - Loss / Misplacement of Share Certificate and Receipt of Application for issuance of Duplicate Share Certificate
Mon, 09 May 2022
Update On Sale / Transfer Of Human Pharma Division (Undertaking) Of The Company
With further reference to our Communication No.TTKH:SEC:GJ:037:22 dated 21st March 2022 on the above subject we wish to inform you that pursuant to the definitive agreements entered into on 21st March 2022 and the approval of the Shareholders by means of a Special Resolution passed through Postal Ballot process the Human Pharma Division (Undertaking) of the Company has been transferred to M/s BSV Pharma Private Limited effective from this date (i.e.) 9th May 2022.
Tue, 03 May 2022
Minutes Of The Proceedings Held On 25Th April 2022 For Declaration Of Results Of The Postal Ballot Process
Certified true copy of the Minutes of the proceedings held on Monday the 25th April 2022 for declaration of results of the Postal Ballot by way of remote e-Voting process for the Special Resolution deemed to have been passed by the Shareholders of the Company on Saturday the 23rd April 2022 being the last date of e-Voting.

Technical Scans View Details

Fri, 20 May 2022
Higher Trade Quantity Higher Trade Quantity
Opening at High Opening at High
Closing Above Previous High Closing Above Previous High
Close Within 52 Week High Zone Close Within 52 Week High Zone
Close Entering 52 Week High Zone Close Entering 52 Week High Zone

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,659.12 915.50 +3.5%
Divi's Laboratories Ltd. 114,020.08 4,295.05 +2.2%
Cipla Ltd. 78,954.82 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. 70,669.41 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. 52,783.35 3,671.00 +1.0%
Gland Pharma Ltd. 50,388.39 3,061.70 -1.1%
Piramal Enterprises Ltd. 45,754.22 1,917.10 +1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 34.09 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 44.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 31.37 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.38 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.57 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 41.59 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 36.83 1,917.10 +1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.25 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 10.53 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 3.79 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.68 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.54 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 7.04 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 1.29 1,917.10 +1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 0.10 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,917.10 +1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,917.10 +1.2%